Dual-Targeted Therapy in Pediatric Inflammatory Bowel Disease: A Comprehensive Review

Yerushalmy‐Feler, Anat; Brauner, Caroline; Cohen, Shlomi

doi:10.1007/s40272-023-00579-6

Pediatr Drugs

2023

DOI: 10.1007/s40272-023-00579-6

|View full text |Cite

Dual-Targeted Therapy in Pediatric Inflammatory Bowel Disease: A Comprehensive Review

Anat Yerushalmy‐Feler

Caroline Brauner

Shlomi Cohen

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Considerations in Paediatric and Adolescent Inflammatory Bowel Disease

Vuijk,

Camman,

de Ridder

2024

Journal of Crohn's and Colitis

View full text Add to dashboard Cite

The incidence of inflammatory bowel disease [IBD] is rising most rapidly among children and adolescents. Paediatric-onset IBD is associated with a more extensive and severe disease course compared to adult-onset IBD. At a young age, screening for underlying genetic and immunological disorders is important and may impact treatment management. Early and effective treatment is crucial to reach disease remission and prevent complications of ongoing active disease. In children with Crohn’s disease, exclusive enteral nutrition is an effective induction therapy. Other promising dietary therapies, such as the Crohn’s disease exclusion diet, are emerging. Within paediatric IBD, anti-tumour necrosis factor therapy is the only approved biological thus far and additional treatment options are crucially needed. Other biological therapies, such as vedolizumab and ustekinumab, are currently prescribed off-label in this population. A specific challenge in paediatric IBD is the unacceptable and major delay in approval of drugs for children with IBD. A guided transfer period of paediatric patients to adult care is associated with improved disease outcomes and is required. Major knowledge gaps and challenges within paediatric IBD include the aetiology, diagnostics, and monitoring of disease, tailoring of treatment, and both understanding and coping with the physical and psychological consequences of living with IBD. Challenges and research gaps in paediatrics should be addressed without any delay in comparison with the adult field, in order to ensure a high quality of care for all patients with IBD, irrespective of the age of onset.

show abstract

Considerations in Paediatric and Adolescent Inflammatory Bowel Disease

Vuijk,

Camman,

de Ridder

2024

Journal of Crohn's and Colitis

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Dual-Targeted Therapy in Pediatric Inflammatory Bowel Disease: A Comprehensive Review

Cited by 1 publication

References 66 publications

Considerations in Paediatric and Adolescent Inflammatory Bowel Disease

Considerations in Paediatric and Adolescent Inflammatory Bowel Disease

Contact Info

Product

Resources

About